RB no longer in discussions with Merck

RB no longer in discussions with Merck

RB Press Release - 30/04/14-Further to the announcement of 28th April, that RB was in discussions with Merck, RB now confirms that it is no longer in active discussion regarding an offer for Merck's consumer health business.

A further announcement will be made, if appropriate, in due course.

For further information, please contact:

Reckitt Benckiser +44 (0)1753 217800

Richard Joyce

Director, Investor Relations

Andraea Dawson-Shepherd

SVP, Global Corporate Communication & Affairs

Brunswick (Financial PR) +44 (0)20 7404 5959

David Litterick 

Cautionary note concerning forward-looking statements

This document contains statements with respect to the financial condition, results of operations and business of RB and certain of the plans and objectives of the Group with respect to these items. These forward-looking statements are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including trends in results of operations, margins, growth rates, overall market trends, the impact of interest or exchange rates, the availability of financing to the Company, anticipated cost savings or synergies and the completion of strategic transactions are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors discussed in this report, that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside Reckitt Benckiser's control. Past performance cannot be relied upon as a guide to future performance.

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.